Jordyn Sava

A study looking at mortality rates from major cancer types may help inform cancer prevention and treatment strategies, and lead to a reduction to the global cancer disparities seen today.

The primary end point of overall survival was not met in the phase 3 SAPPHIRE study of sitravatinib plus nivolumab in patients with advanced non-squamous non–small cell lung cancer.

If granted approval, fruquintinib will be the first and only highly selective inhibitor of all 3 VEGF receptors to be approved in the United States for patients with metastatic colorectal cancer.

In an interview with Targeted Oncology, Andreas Varkaris, MD, PhD, discussed findings from the ReDiscover trial and treating patients with PIK3CA mutations.

When used as a monotherapy or in combination with venetoclax, voruciclib was generally well tolerated and showed an encouraging preliminary efficacy signal in patients with acute myeloid leukemia or B-cell malignancies.

Ropeginterferon alfa-2b-njft was added to the NCCN guidelines and granted category 2A status for the treatment of polycythemia vera.

Bill 1196 / Assembly Bill 1673 aims to improve access to precision medicine for patients with cancer in New York by requiring all state-regulated health plans to cover biomarker testing when it is supported by medical and scientific evidence.

In an interview with Targeted Oncology, Pedro Barata, MD, MSc, discussed the current therapies available, unmet needs, and ongoing studies for patients with metastatic prostate cancer.

Mitazalimab has received an orphan drug designation from the FDA and is currently being investigated in the OPTIMIZE-1 trial in combination with modified FOLFIRINOX for the treatment of patients with pancreatic cancer.

The FDA has approved avapritinib for adult patients with indolent systemic mastocytosis based on findings from the phase 2 PIONEER trial.

Data on SC-DARIC33 reinforce the potential of the agent as a new T-cell therapy approach for patients with acute myeloid leukemia.

While cabozantinib, nivolumab, and ipilimumab resulted in a longer progression-free survival among patients with renal cell carcinoma vs nivolumab and ipilimumab alone, more adverse events were observed with the combination.

In an interview with Targeted Oncology, Craig Horbinski, MD, PhD, discussed recent recommendations and NCCN guidelines regarding the molecular profiling of gliomas and other central nervous system cancers.

In an interview with Targeted Oncology, Tycel Phillips, MD, discussed what led to the FDA approval of subcutaneous epcoritamab for patients with relapsed/refractory diffuse large B-cell lymphoma and how it adds to the current treatment landscape.

In an interview with Targeted Oncology, Salman Fazal, MD, discussed differences between older matched sibling donors vs younger unrelated donors in stem cell transplants and donor preferences at his institution for patients with cancer.

A phase 3 trial evaluating roxadustat for the treatment of anemia in patients receiving concurrent chemotherapy for non-myeloid malignancies met its primary end point.

Rucosopasem manganese is being investigated in the phase 1/2 GRECO-1 and phase 2b GRECO-2 trials in combination with stereotactic body radiation therapy for the treatment of patients withlj non–small cell lung cancer and pancreatic cancer.

The FDA has provided positive feedback in establishing further research for eftilagimod alpha in frontline non–small cell lung cancer.

The FDA has requested additional information regarding vic-trastuzumab duocarmazine to further evaluate the agent for patients with HER2-positive metastatic breast cancer.

Adult patients with chronic lymphocytic leukemia had significantly better minimal residual disease and progression-free survival results when treated with venetoclax and obinutuzumab or venetoclax, obinutuzumab, and ibrutinib vs standard chemoimmunotherapy

Positive findings from the FLAURA2 study add to the body of evidence supporting treatment with osimertinib for patients with EGFRm non–small cell lung cancer.

The fast track designation to IMPT-314 is for the treatment of multiple types of B-cell lymphoma in patients who previously received 2 or more lines of systemic therapy.

The FLASH study and compatibility study of SGX301 led to promising safety and efficacy responses for the treatment of cutaneous T-cell lymphoma. Now, the FDA has granted a type A meeting to discuss the design of a second trial of SGX301.

In an interview, Ruben Mesa, MD, discussed the currently available JAK inhibitors for patients with myelofibrosis, and what is in store for the field.

The phase 3 RATIONALE-306 study displayed encouraging survival and safety data among patients with advanced or metastatic esophageal squamous cell carcinoma who were treated with tislelizumab and chemotherapy.

The proportion of patients with myelodysplastic syndromes who achieved red blood cell transfusion independence in the first 28 weeks was 47.5% for patients given roxadustat vs 33.3% for patients given placebo for the treatment of anemia.

A study of patients with relapsed/refractory diffuse large B-cell lymphoma has showed that continuous administration of PD-1 inhibitors as a maintenance treatment may be feasible to maintain the efficacy of anti-CD19-CAR T cells.

ACR-368 generated deep and durable responses across several phase 2 studies. The agent has now been granted fast track designations for patients with platinum-resistant ovarian cancer and endometrial cancer.

FDA approval has not been granted to N-803 for the treatment of Bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ.